In conclusion, both BCG immune stimulation at early disease stage and anti‐PD‐1/PD‐L1 ICB at late disease stage are effective immunotherapies for bladder cancer, due to its molecular/biological characteristics and unique anatomical structure and location. The gene discussed is CD274; the disease is urinary bladder carcinoma.